Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial
Objectives Bench to bedside translation of groundbreaking treatments like chimeric antigen receptor T (CAR-T) cell therapy depends on patient participation in early phase trials. Unfortunately, many novel therapies fail to be adequately evaluated due to low recruitment rates, which slows patient acc...
Saved in:
| Main Authors: | Dean A Fergusson, Manoj M Lalu, Justin Presseau, Kednapa Thavorn, Joshua Montroy, Natasha Kekre, Gisell Castillo, Sarah Asad, Madison Foster, Terry Hawrysh, Harold Atkins, Stuart Schwartz, Robert A Holt, Raewyn Broady |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-03-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/3/e043929.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy
by: Dean A Fergusson, et al.
Published: (2021-08-01) -
What are potential barriers and enablers to patient and physician participation in Canadian cell therapy trials for stroke? A stakeholder interview study
by: Dean A Fergusson, et al.
Published: (2020-03-01) -
Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
by: Dean A Fergusson, et al.
Published: (2019-12-01) -
Prospective randomised controlled trial using the REthinking Clinical Trials (REaCT) platform and National Surgical Quality Improvement Program (NSQIP) to compare no preparation versus preoperative oral antibiotics alone for surgical site infection rates in elective colon surgery: a protocol
by: Dean A Fergusson, et al.
Published: (2020-07-01) -
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22
by: Scott McComb, et al.
Published: (2024-03-01)